Bain Capital Life Sciences Investors, LLC
About Bain Capital Life Sciences Investors, LLC’s 13F portfolio
Bain Capital Life Sciences Investors, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Bain Capital Life Sciences Investors, LLC reported $1.7B across 21 US-listed positions (). Its largest position is KAILERA THERAPEUTICS INC (KLRA) at 30% of the reported book, and its ten biggest holdings make up 88% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: KLRA KAILERA THERAPEUTICS INC | — — | 30% | 22.6M | $497.5M |
| 2 | NASDAQ: HTFL HEARTFLOW INC | $44.63 −2.75% | 15% | 8.4M | $247.9M |
| 3 | NASDAQ: NAMS NEWAMSTERDAM PHARMA COMPANY | $19.51 −1.17% | 7.7% | 3.8M | $129.0M |
| 4 | NASDAQ: SVRA SAVARA INC | $5.21 +10.38% | 6.4% | 17.6M | $108.4M |
| 5 | NASDAQ: ALKS ALKERMES PLC | $46.18 −1.43% | 6.0% | 1.9M | $101.5M |
| 6 | NASDAQ: SLDB SOLID BIOSCIENCES INC | $6.44 +1.42% | 5.8% | 9.8M | $98.0M |
| 7 | NASDAQ: PHVS PHARVARIS N V | $31.66 +0.35% | 5.5% | 2.7M | $92.5M |
| 8 | NASDAQ: OLMA OLEMA PHARMACEUTICALS INC | $7.15 +1.27% | 5.3% | 7.1M | $88.6M |
| 9 | NASDAQ: COAG HEMAB THERAPEUTICS HOLDINGS INC | — — | 3.6% | 1.6M | $60.6M |
| 10 | NASDAQ: CABA CABALETTA BIO INC | $1.01 −4.27% | 3.2% | 17.2M | $53.6M |
| 11 | NASDAQ: XFOR X4 PHARMACEUTICALS INC | $2.96 −0.67% | 2.2% | 8.0M | $37.2M |
| 12 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | $84.83 +1.01% | 2.1% | 362K | $35.3M |
| 13 | NASDAQ: CCCC C4 THERAPEUTICS INC | $2.44 −1.41% | 2.0% | 7.2M | $33.5M |
| 14 | NASDAQ: KYTX KYVERNA THERAPEUTICS INC | $4.37 −2.46% | 1.5% | 2.9M | $25.7M |
| 15 | NASDAQ: ANNX ANNEXON INC | $3.41 −3.12% | 1.5% | 4.4M | $25.3M |
| 16 | NASDAQ: RPID RAPID MICRO BIOSYSTEMS INC | $0.74 −0.31% | 0.9% | 8.4M | $14.6M |
| 17 | NASDAQ: IRON DISC MEDICINE INC | $76.11 −2.40% | 0.6% | 141K | $10.3M |
| 18 | NASDAQ: AVIR ATEA PHARMACEUTICALS INC | $3.93 −1.50% | 0.6% | 2.1M | $9.7M |
| 19 | NASDAQ: XLO XILIO THERAPEUTICS INC | $7.51 −1.57% | 0.4% | 664K | $6.4M |
| 20 | NASDAQ: UPB UPSTREAM BIO INC | $2.00 −3.85% | 0.2% | 601K | $4.2M |
| 21 | NASDAQ: NAMSW NEWAMSTERDAM PHARMA COMPANY | $9.49 0.00% | 0.1% | 100K | $2.1M |
Showing the 21 largest positions reported in this 13F.
- Healthcare67%
- NewKLRAKAILERA THERAPEUTICS INC—$497.5M
- AddedALKSALKERMES PLC+218%$101.5M
- NewCOAGHEMAB THERAPEUTICS HOLDINGS INC—$60.6M
- AddedCABACABALETTA BIO INC+78.2%$53.6M
- ReducedHTFLHEARTFLOW INC−19.1%$247.9M
- ReducedNAMSNEWAMSTERDAM PHARMA COMPANY−47.9%$129.0M
- ReducedOLMAOLEMA PHARMACEUTICALS INC−5.2%$88.6M
- ReducedKYTXKYVERNA THERAPEUTICS INC−7.2%$25.7M
- ReducedANNXANNEXON INC−14.9%$25.3M
- ReducedAVIRATEA PHARMACEUTICALS INC−12.1%$9.7M
- ReducedUPBUPSTREAM BIO INC−30.7%$4.2M
- SoldCNTACENTESSA PHARMACEUTICALS−100%—
Reading Bain Capital Life Sciences Investors, LLC’s 13F portfolio
Bain Capital Life Sciences Investors, LLC’s $1.7B 13F book is spread across 21 reported positions and is highly concentrated — its ten largest positions alone are 88% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are KLRA, HTFL, NAMS, SVRA and ALKS, led by KAILERA THERAPEUTICS INC (KLRA) at 30% of the portfolio. The heaviest sector exposure is Healthcare (67%).
What Bain Capital Life Sciences Investors, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Bain Capital Life Sciences Investors, LLC was a net seller: it opened 2 new positions and added to 2 more, while trimming 7 and closing 1 outright. Against a 21-name book, that is moderate turnover, pointing to steady rotation within the portfolio. Its largest new or increased position was KAILERA THERAPEUTICS INC (KLRA), and its biggest reduction was HEARTFLOW INC (HTFL).
What a 13F does and doesn’t reveal
A 13F captures only Bain Capital Life Sciences Investors, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Bain Capital Life Sciences Investors, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Bain Capital Life Sciences Investors, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Bain Capital Life Sciences Investors, LLC's page?
It reflects Bain Capital Life Sciences Investors, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Bain Capital Life Sciences Investors, LLC files its next quarterly report, this page refreshes automatically.
Can I see Bain Capital Life Sciences Investors, LLC's complete list of holdings?
This page highlights Bain Capital Life Sciences Investors, LLC's largest positions rather than all 21 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Bain Capital Life Sciences Investors, LLC's filings.
Does a 13F show everything Bain Capital Life Sciences Investors, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Bain Capital Life Sciences Investors, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Bain Capital Life Sciences Investors, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

